Monopar Therapeutics MNPR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's stock-based comp?
- Monopar Therapeutics (MNPR) reported stock-based comp of $1.69M in Q1 2026.
- How has Monopar Therapeutics's stock-based comp changed year-over-year?
- Monopar Therapeutics's stock-based comp increased by 24.9% year-over-year, from $1.36M to $1.69M.
- What is the long-term trend for Monopar Therapeutics's stock-based comp?
- Over 3 years (2022 to 2025), Monopar Therapeutics's stock-based comp has grown at a 43.4% compound annual growth rate (CAGR), from $1.64M to $4.84M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.